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Abstract: In recent years, metabolomics has attracted great scientific attention. The metabolomics
methodology might permit a view into transitional phases between healthy liver and nonalcoholic
steatohepatitis. Metabolomics can help to analyze the metabolic alterations that play a main role in
the progression of nonalcoholic steatohepatitis. Lipid, glucose, amino acid, and bile acid metabolism
should be widely studied to understand the complex pathogenesis of nonalcoholic steatohepatitis.
The discovery of new biomarkers would be important for diagnosis and staging of liver disease as
well as for the assessment of efficacy of new drugs. Here, we review the metabolomics data regarding
nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. We analyzed the main studies
regarding the application of metabolomics methodology in the complex context of nonalcoholic
steatohepatitis, trying to create a bridge from the basic to the clinical aspects.
Keywords: liver metabolomics; translational medicine; hepatic metabolism
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) represents the most common cause of chronic liver
disease in the Western countries [1]. The clinical-histologic phenotype of NAFLD ranges from
nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH). NASH is characterized not
only by fat accumulation, but also by inflammation, ballooning degeneration, necro-apoptosis, and
fibrosis. Notably, in about one third of patients, NASH can progress up to cirrhosis, hepatocellular
carcinoma, and end-stage liver disease [2]. NASH represents a major clinical issue affecting about 1%
of the European and North American population [3] and in recent years it has become one of the main
causes for liver transplantation [4].
The alteration of glucose and lipid metabolism has a central role in the pathogenesis of NASH.
In fact, patients with NASH often show insulin resistance (IR), central obesity, reduced glucose
tolerance, type 2 diabetes mellitus (T2DM), arterial hypertension, and hypertriglyceridemia [5,6].
Liver biopsy is the gold standard for the diagnosis of NASH [7]. However, the invasiveness
and the sampling variability are major unresolved issues [7]. Indeed, it is not surprising that many
researchers have proposed some non-invasive markers of both steatosis and fibrosis [8].
The lack of a widely approved therapeutic approach represents another major concern.
Today, the standard of care for the treatment of NASH is lifestyle improvement [2]. However, the effect
of lifestyle intervention on liver histology needs further evaluation, as there is a lack of evidence
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about the optimal dietary nutrient composition and exercise requirement. On the other hand,
vitamin E and pioglitazone are the only approved pharmacological options for patients with NASH.
Nevertheless, there are noteworthy limits concerning efficacy and long-term safety [2].
In this scenario, the discovery of new biomarkers of NAFLD/NASH useful for diagnosis, staging,
and assessment of efficacy of new drugs is an important scientific goal.
Metabolomics might be an interesting tool for this aim since it can be applied for the early
diagnosis of liver disease, for better understanding the pathogenesis, and for the development of new
drugs [9]. Metabolomics, with other “omics” technologies, might support the accurate understanding
of biochemical events inside the cells. Metabolomics represents a new and powerful technology for
biomarker detection within a dynamic field. Together with genomics, transcriptomics, and proteomics,
metabolomics can lead to a wide knowledge of biological systems [9].
Although the term “metabolomics” and the related techniques have been only recently adopted,
some simple applications of the metabolomics concept date back to many centuries ago. An example
is the “urine wheel”, published in 1506 by Ullrich Pinder in the book entitled Epiphanie Medicorum [10].
The liver represents the main source of many endogenous metabolites, precursors, and detoxification
enzymes [11]. The liver metabolome includes a complex and dynamic flux of small metabolites
(by definition <1.5 kDa). Mass spectrometry (MS)-based techniques such as gas chromatography/MS,
liquid chromatography (LC)/MS, nuclear magnetic resonance (NMR) spectroscopy, and Fourier transform
infrared spectroscopy (FTIR), represent the applied techniques for an appropriate metabolomics analysis.
Notably, the different technologies enable one to obtain a wide view of metabolite profiles [12].
In the clinical practice, the detected and quantified biomarkers can be used as unbiased indicators of
illness onset and progression and as support for disease classification. Biomarkers might become prognostic
indicators that could be used for risk stratification of the general population. Moreover, the metabolomics
approach might be useful for the early diagnosis of liver disease and for assessing the efficacy of new
therapeutic interventions.
Herein, we describe the main animal and human studies concerning the application of
a metabolomics approach in the NAFLD context. We conducted a complete PubMed Literature search
using the key terms “non-alcoholic fatty liver disease”, “non-alcoholic steatohepatitis”, as well as the
name of each known biomarker. Articles indexed between 2000 and 2017 were analyzed. We examined
some crucial metabolic pathways involved in liver disease, including altered key metabolic pathways
such as cellular energy metabolism, lipid and glucose metabolism, amino acid pathways, metabolism of
bile acids (BAs), and oxidative stress.
2. Metabolic Alterations of NAFLD
2.1. Modification of Lipid Metabolism
It is well known that NAFLD is characterized by significant increase of lipid species in both
the blood and liver tissue. Disruption of lipid balance consists of changes in cholesterol esters,
triacylglycerols (TG), diacylglycerols, and sphingomyelins [13–16]. Puri et al. [17] compared plasma
lipids and eicosanoid metabolites quantified by MS in three subgroups: simple NAFL, NASH,
and healthy controls (HC). Both patients with NAFL and subjects with NASH showed a noteworthy
rise of total monounsaturated fatty acids due to palmitoleic and oleic acids and an increase of
gamma-linolenic and dihomo gamma-linolenic acids. Notably, palmitoleic acid, oleic acid, and the
palmitoleic acid to palmitic acid ratio were considerably augmented in patients with NAFL.
The increased turnover of phospocholine (PC) and phosphatidylethanolamine species in
the liver represents another important topic emerging from NAFLD/NASH animal models.
Interestingly, it determines the release of free fatty acids through the action of phospholipases A1 and A2
that are not catabolized by β-oxidation, and therefore get stored in the liver as TG [13–15].
Remarkably, fatty liver accumulation is not just a fat deposition in the liver but rather a “reorganization”
of lipid storage [13]. Van Ginneken et al. [13], using a 24-h starvation mice protocol, demonstrating that
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adipose tissue was the main source of liver TG. They demonstrated that animals with fatty liver showed
increased hepatic concentrations of lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE),
and PC species. [18]. On the other hand, Pereira et al. [19] reported that obese female Sprague–Dawley rats
developed an increase in diacylglycerol and a drop in phosphatidylethanolamine in comparison with lean
animals. Moreover, the expression of both phosphoethanolamine cytidylyltransferase and peroxisomal
proliferator activated receptor-α mRNA was lessened in the hepatic tissue of obese rats compared to
the others.
Kalhan et al. [16] developed a metabolomics study enrolling 11 non-diabetic subjects with
histologically proven steatosis, 24 with NASH, and 25 healthy controls (HC). Many free fatty acids
such as eicosopentaenoate, docosohexaenoate, 10-undecenoate, and arachidonate were significantly
lower in patients with NASH in comparison with HC. Notably, only caprate and 10-undecenoate were
significantly lower in subjects with NAFL in comparison with HC. Finally, linolenate and undecanoate
were considerably increased in subjects with NAFL in respect to NASH.
Interestingly, Tu et al. [20] tried to clarify the pathogenesis of non-obese NAFLD that definitely
represents clinical unresolved issues. They demonstrated that systemic mechanisms leading to steatosis
and liver damage in the non-obese mouse model were due to a mixture of effects of elevated free
cholesterol, cholesterol esters, and cholic acid, and related modifications of sphingomyelin and
phosphatidylcholine metabolism. Remarkably, the authors described one of the first metabolite
reference profiles useful for understanding the properties of dietary and hepatic cholesterol in
non-obese human NAFLD subjects.
Papandreou et al. [21] analyzed the rearrangement of lipid biosynthesis occurring in patients
with non-alcoholic liver steatosis with a follow-up period of 3.8 years. They subdivided 45 patients
into the following subgroups: (1) HC; (2) liver steatosis; (3) liver steatosis reversion during the
follow-up. At baseline, patients with liver steatosis displayed lesser storage and transport of TG and
cholesteryl esters, several monoetherglycerophosphocholines, acylglycerophosphocholines, ceramides,
and ceramide to sphingomyelin ratio in comparison with HC. P-ether acylglycerophosphocholines,
ceramides, and sphingolipids were significantly dissimilar between group 3 and group 1. Interestingly,
the alterations of metabolic profile were found not only in patients with liver steatosis but also in
patients with liver steatosis reversion, probably because the negative metabolic condition required a
long time period for complete regression.
2.2. Glucose Metabolism
In animal models of NASH, glucose concentrations can be decreased in both the serum [22] and
liver tissue [23]. Toye et al. [24] analyzed glucose tolerance, in vivo insulin secretion, the plasma
lipid profile, and adiposity of mice with high fat diet-induced NAFLD. According to the authors,
the increased plasma lactate concentrations in fat-fed mice might indicate muscle lactate production
due to hyperglycemia. In general, NAFLD seems to favor the cytosolic glycolysis with a rise of
serum/plasma lactate, pyruvate, and alanine [24]. Notably, the onset of IR represents one of the
main negative turning points in the pathogenesis of NAFLD and NASH [2]. In the mouse model
of liver steatosis, the rise of insulin levels and the associated activation of pyruvate kinase M2 can
favor glycolysis and the consequent increased production of lactate and alanine from glucose via
pyruvate [25]. Kalhan et al. [16] showed that glucose and pyruvate were markedly higher in subjects
with NASH. Mannose, lactate, and erythronate levels were more pronounced in both steatosis and
NASH than HC.
2.3. Amino Acids
Patients with liver disease usually show wide modification of essential amino acids and common
branched-chain amino acids (such as valine, leucine, and isoleucine). Leucine, isoleucine, and valine
might mediate activation of several important hepatic metabolic signaling pathways ranging from
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insulin signaling to glucose regulation [9]. It is therefore not surprising that they have a significant role
in the management of NAFLD and NASH.
García-Canaveras et al. [18] reported that in patients with NAFLD in contrast to the others,
an impaired recycling of amino acids could be found. This imbalance of amino acid homeostasis might
determine an alteration of glutamate, glutamine, and glutamyl-peptide.
Kalhan et al. [16] described a rise of glycochenodeoxycholate, glycocholate, and taurocholate
in the subgroup of patients with NAFL. In patients with NASH, free carnitine, butyrylcarnitine,
and methylbutyrylcarnitine increased while long-chain fatty acids decreased. The cysteine-glutathione
level was lower in NASH and NAFL, while glutamyl dipeptides were higher in comparison with
HC. Notably, it was demonstrated that in patients with NAFLD, cysteine-glutathione disulfide and
oxidized/reduced glutathione declined in both liver tissue [18] and blood [16], representing a clear
sign of active oxidative stress.
Goffredo et al. [26] analyzed the disorders of amino acid metabolism in obese young people with
NAFLD. The metabolomics signature of 78 obese adolescents with or without NAFLD was analyzed.
Subjects with NAFLD showed higher plasma levels of valine, isoleucine, tryptophan, and lysine.
Interestingly, it was demonstrated that a higher baseline valine level could represent a strong predictor
of major hepatic fat accumulation.
Kaikkonen et al. [27] proposed another study about NAFLD in young adults. Interestingly, they
focused on the metabolic perturbations preceding the onset of liver disease. Sera from the population-based
Young Finns Study were analyzed (year 2001, n = 1575; year 2007, n = 1509; year 2011, n = 2002).
The presence of NAFLD was assessed in 2011. Extremely large very-low-density lipoprotein TG,
very-low-density lipoprotein measures, and branched-chain amino acids were strongly associated with
the onset of liver disease. Notably, high-density lipoprotein measures and several fatty acids including
omega-6 were inversely related to NAFLD development.
2.4. Bile Acids
BAs are important signaling molecules for both lipid and glucose homeostasis. Chenodeoxycholic
and deoxycholic acids are endogenous ligands of farnesoid X receptor (FXR) that is a key metabolic
receptor [28]. In the liver, FXR modulates the conversion of cholesterol to BAs by regulation of the
expression of cytochrome p450 7A1. FXR also induces the expression of the canalicular bile salt export
pump and multidrug resistance-associated protein 2. In the ileum, FXR receptor decreases the uptake of
BAs through a down-regulation of the sodium-dependent BA transporter. Furthermore, FXR improves
expression of ileal BA-binding protein, which acts as a shuttling device for the transport of BAs to the
basolateral membrane of erythrocytes. Remarkably, FXR inhibits both the hydroxymethylglutaryl-CoA
reductase and the lanosterol 14 α-demethylase that play central roles in cholesterol synthesis [28].
A four-fold increase in the plasma concentration of glycocholate and taurocholate, and a two-fold
increase in glycochenodeoxycholate were found in patients with NASH vs. HC [16]. These BAs were
also higher in patients with steatosis compared with HC (but only taurocholate reached statistical
significance). García-Canaveras, et al. [18], using a LC-MS-based metabolomics analysis, evaluated 23
steatotic and 23 non-steatotic human livers. It was confirmed that patients with steatosis showed
higher levels of BAs and phospholipid degradation products compared to the others.
3. Metabolomics Profile Modifications: NAFL vs. NASH
3.1. Animal Studies
As indicated in the previous paragraphs, NASH represents the most dangerous expression of
the NAFLD spectrum [2]. Notably, only a few metabolomics studies have investigated the complex
mechanisms leading to the progression from simple NAFL toward NASH and NASH-cirrhosis.
Li et al. [22] used a methionine and choline deficient (MCD) diet to describe different stages of
NAFLD in male C57BL/6 mice. With a proton nuclear magnetic resonance approach, the showed that
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betaine, PC, choline, and trimethylamine N-oxide were up-regulated in both the liver and plasma
of fatty liver rodents. Serum glucose, glutamate/glutamine, lactate, and taurine were identified as
biomarkers of NAFLD. Furthermore, a model was built to predict the NAFLD progression rate based
on the different levels of these four biomarkers.
Tanaka et al. [29] analyzed NASH pathogenesis, combining high-end analytics and targeted
gene expression. They induced a NASH-like disease in mice fed a MCD diet and compared them
with normal diet animals. They demonstrated a significant decrease of LPC with a related rise in
tauro-β-muricholate, taurocholate, and 12-hydroxyeicosatetraenoic acid. Moreover, it was suggested
that the decrease of LPC and the increase of serum BAs could represent a sign of inflammation. In fact,
phospholipid and BA metabolism was altered in NASH but not in simple steatosis.
Zhao et al. [30] further investigated the modifications of LPC and BA homeostasis in the NASH
model. In particular, they quantified the hepatic mRNA levels related to genes involved in the
metabolism and transport of LPC, Bas, and 12-hydroxyeicosatetraenoic acid. In mice with NASH, LPC
acyltransferases (LPCAT) (that convert LPC to PC) were up-regulated by two- to four-fold. The above
reported findings might clarify how the inflammatory phenotype of NASH in the mouse model results
in the variations of serum metabolites. Notably, similar alterations have been described patients with
NASH [16], suggesting that similar mechanisms can operate in humans.
Recently, Alonso et al. [31] analyzed liver tissue and serum from methionine adenosyltransferase
1a knockout (MAT1A-KO) and C57Bl/6 (controls) mice. Animals showed chronically low levels
of hepatic S-adenosylmethionine (SAMe), which plays a key role in the maintenance of cellular
homeostasis and cell cycle control, and in NASH-like liver disease. It was demonstrated that deletion
of MAT1A, an integrator of the cellular metabolic status, might not only affect hepatic metabolism
downstream of SAMe, but also leads to an imbalance in the circulation of one-carbon units from
specific amino acids to folates, thus altering the biosynthesis of lipids, proteins, and amino acids,
and mitochondrial polarization and function. Notably, it was suggested that the described changes
might favor NASH onset. Indeed, altered SAMe level might be a significant determinant that might
cause the switch from NAFL to NASH. Remarkably, the authors’ conclusions are coherent with
the finding that NASH patients with advanced liver disease tend to develop a decreased MAT1A
expression [32].
In contrast with Alonso et al. [31], Del Bas et al. [33] demonstrated that animals with metabolic
syndrome and NASH developed an unexpected accumulation of hepatic SAMe. Consequently,
progression of NAFLD in the context of metabolic syndrome could happen even in a state of hepatic
SAMe excess.
In this complex context, Liu et al. [34] performed an extensive study of different NAFLD
phenotypes, using a high-fat diet, a MCD diet, and streptozocin in different rat models to compare
NAFL, NASH, and NAFL + T2DM. Transcriptomics and metabolomics tests were conducted in both
liver tissue and serum samples. Ninety-six genes, 17 liver metabolites, and 4 serum metabolites reliably
changed. Notably, stearoyl-carnitine was the only metabolite modified in both liver and serum of the
three NAFLD phenotypes. The analyzed genes and metabolites showed a noteworthy role in lipid,
glucose, and fatty acid metabolism and in the immune and inflammatory response.
3.2. Human Studies
Kalhan et al. [16] conducted a small study analyzing data from 11 non-diabetic subjects with
histologically proven steatosis, 24 with NASH, and 25 HC. Notably, only some metabolites were
significantly different in the plasma of subjects with NAFL and NASH. Glutamate, creatine, pyruvate,
unknown X-01911_200, were lower in patients with NAFL compared to NASH, while undecenoate
and linolenate were considerably higher.
Puri et al. [17] presented a study comparing plasma lipids and eicosanoid metabolites quantified
by MS in patients with NAFL or NASH versus HC. Notably, NASH patients showed a reduction in the
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docosahexanoic acid to docosapentenoic acid ratio and a rise in the level of 11-hydroxyeicosatetraenoic
acid (arachidonic acid’s derivate).
Barr et al. [35] developed a translational study with both humans (NAFLD and HC) and an
animal model (Gnmt-KO mice) using a global metabolite profiling methodology. In NAFLD samples,
the levels of organic acids, PC, LPC, arachidonic acid, glutamic acid, Bas, and sphingomyelin lipids
were significantly altered. The amount of deoxycholic acid was significantly higher in NAFLD versus
normal liver. A further analysis was dedicated to find the differences between human NAFL and NASH.
Significant changes in serum concentrations were found in antioxidative ether glycerophospholipids,
sn-2 arachidonly diacylglycerophosphocholine, and free arachidonic acid (the latter two with a relevant
role in eicosanoid signaling pathways). Interestingly, the same first author [36] studied a large sample
size (467 biopsied individuals with normal liver histology, NAFL, or NASH), observing comparable
phenotypes in humans and mice with NASH, such as reduced levels of poly-unsaturated fatty acids,
sphingomyelin, and a number of LPC species. In patients with NASH, high acyl carnitines (sign of
mitochondrial β-oxidation dysfunction), altered ether phospholipids, and boosted proinflammatory
eicosanoids can be detected.
Han et al. [37] proposed another translational human-animal study. In this study, the main metabolic
pathways associated with progression of NASH were analyzed. They reported that metabolome
changes in both humans and the rat model of NASH mainly concerned amino acid and BA metabolism.
Notably, the study underlined some relevant differences between the metabolomics data from animals
and humans, mainly regarding the biochemical pathogenesis of NASH. Taurine, an organic acid that
conjugates BAs, was considerably boosted in human NASH but not in the animal model. Moreover,
betaine and creatine exhibited reverse modification between animals and humans. Indeed, selected
essential amino acids could be potential biomarkers for liver disease progression and the mixture of
metabolomics variations of BAs, amino acids, and fatty acids could help to better understand the
pathogenesis of NASH.
Recently, Dong et al. [38] identified some biomarkers that may be different according the NAFLD
stage. They analyzed urine and blood of the following subgroups of patients: non-diabetic patients
with NAFLD and normal liver function (n = 33), NASH with impairment of liver function (n = 45),
and HC (n = 30). Compared to the HC, patients with NASH displayed higher urinary levels of lysine,
valine, citrulline, arginine, threonine, tyrosine, leucine, hippuric acid, and 3-indoleacetic acid but
also decreased levels of derivatives of indole acetic acid, such as 5-hydroxy indole acetic acid and
indole-3-formic acid. Moreover, their cortisol level considerably dropped. It was demonstrated that
2-methylguanosine, gluconic acid, indoxylsulfuric acid, cAMP, indolelactic acid, and acetyl-DL-leucine
were able to discriminate patients with NASH and HC. Patients with NASH showed higher levels of
methyl xanthine, tryptophan, 3-indole acetic acid, and gluconic acid, and lower proline. As demonstrated
by the ROC analysis, 3-indoleacetic acid, L-carnitine, pyroglutamic acid, and indolelactic acid might
differentiate NASH from NAFLD.
Lake et al. [39] analyzed the complex progression of steatosis toward NASH by metabolomic
and transcriptomic analysis. They reported rises in the levels of leucine (+127%), isoleucine (+139%),
and valine (+147%) from NAFL to NASH. Also, carnitine metabolites were significantly elevated in
NASH compared to NAFL.
Sokooian et al. [40], in a two-stage case-control study, included patients with biopsy-proven
NAFLD and investigated the circulating levels of betaine and its association with the histological
spectrum. Betaine level correlated with the disease severity and with liver inflammation, ballooning
degeneration, and fibrosis. Betaine concentration was considerably decreased in NASH patients in
comparison with NAFL. The role of betaine in the modulation of the methylome is relevant as the
process of methylogenesis is exclusively active in the liver that represents a large betaine reservoir.
O’Sullivan et al. [41] used an integrated, non-targeted metabolomics, genetic, and human
phenotyping study to analyze the role of dimethylguanidino valeric acid (DMGV) as a biomarker of
NAFLD in individuals undergoing gastric bypass surgery. Plasma DMGV levels showed a relevant
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correlation with biopsy-proven NASH. In detail, DMGV levels fell in parallel with improvements of
cardio-metabolic parameters. Remarkably, the baseline DMGV level was an independent predictor of
long-term T2DM. The main patterns of the human-based available studies are summarized in Table 1.
Table 1. Main patterns of human-based Metabolomics studies about NAFLD.
First Author Sample Size # Method Main Findings Reference
Kalhan 60 LC; GC; MS
(1) Glutamate, creatine, pyruvate, unknown
X-01911_200, were lower NAFL than NASH;
(2) undecenoate and linolenate higher
[16]
Puri 125 MS
(1) Patients with NASH exhibited a decrease of
docosahexanoic acid to docosapentenoic acid ratio
and a rise of 11-hydroxyeicosatetraenoic acid than
NAFL and HC
[17]
Barr 42 LC; MS
(1) Deoxycholic acid was higher in NAFLD versus
normal liver; (2) antioxidative ether
glycerophospholipids, sn-2 arachidonly
diacylglycerophosphocholine, and free arachidonic
acid were different between NAFL and NASH
[35]
Barr 467 LC; MS (1) High serum NEFA in NAFLD patients; (2) LowNEFA and elevated acyl carnitines in NASH [36]
Han 58 LC; MS
(1) The short-chain carnitines were higher in
NASH; (2) long-chain fatty acid and phospholipids
lower in NASH respect to the others; (3) significant
dissimilarities between human NAFLD
progression and rodent models
[37]
Dong 108 LC; MS
(1) Carnitine in urine was lower in NAFLD patients
than in HC; (2) amino acids were higher in patients
with NASH patients than in HC; (3) cholinesterase
was lower in patients with NASH than NAFL;
(4) level of indoleacetic acid was higher in the
NASH group compared with NAFL
[38]
Lake 45 LC; MS
(1) NASH patients show higher levels of leucine,
isoleucine, valine in respect to NAFL; (2) carnitine
metabolites were higher in NASH than NAFL
[39]
Sokooian 99 LC; MS (1) Patients with NASH showed a 1.26-folddecrease in betaine levels than NAFL [40]
O’Sullivan 470 LC; MS
(1) DMGV levels increased in the presence of
NASH; (2) DMGV levels fell in parallel with
metabolic improvements
[41]
LC, liquid chromatography; MS, mass spectrometry; GC, gas chromatography; NAFL, Non-Alcoholic Fatty Liver;
NASH, Non-alcoholic Steatohepatitis; HC, Healthy Controls; NEFA, Non-esterified fatty acids; NAFLD, Non-Alcoholic
Fatty Liver Disease; DMGV, Dimethylguanidino valeric acid. # Number of human subjects involved (parallel animal
models are not computed).
4. Integrated Clinical Points of View
To gain real insight in the pathogenesis of human liver damage and in the progression of NAFLD,
experimental data need to be bridged to the clinical condition. At least three studies have been
performed toward this goal with noteworthy results.
Calvo et al. [42] verified in an observational, prospective, single-site, 1-year cross-sectional study
showing the usefulness of magnetic resonance imaging (MRI) and spectroscopy (MRS) for assessment
of NAFLD in patients undergoing bariatric surgery. They utilized the H NMR-based metabolomics
approach. MRI data showed a pronounced relationship with the histological assessment (such as liver
TG). The increased levels of TG and monounsaturated fatty acids in severe steatosis were associated
with a substantial reduction in diglycerides, polyunsaturated fatty acids, glucose-6-phosphate, and the
ATP/AMP ratio.
Zhou et al. [43] proposed a large study (318 subjects) comparing the MS-based profiling of plasma,
the routinely available clinical parameters, and the patatin-like phospholipase domain-containing
protein 3 (PNPLA3) genotype as potential tools for diagnosis of NASH. They developed the NASH
ClinLipMet Score that includes glutamate, isoleucine, glycine, LPC, phosphoethanolamine, AST,
Metabolites 2018, 8, 17 8 of 12
and fasting insulin, along with PNPLA3 genotype. The “NASH ClinLipMet” score was able to
identify patients with NASH with a relevant ROC value [0.866 (95% confidence interval, 0.820–0.913)],
which was significantly higher than “NASH Clin Score” [0.778 (95% confidence interval, 0.709–0.846)].
More recently, Del Chierico et al. [44] analyzed the gut microbiota of pediatric NAFLD patients
with both metagenomics and metabolomics methodologies. They enrolled 61 patients with NAFL,
NASH, or obesity, and 54 HC. In comparison with HC, a decrease of Oscillospira in NAFL and
NASH groups and an increase in species such as Ruminococcus, Blautia, and Dorea was detected.
The study of Oscillospira, Rickenellaceae, Parabacteroides, Bacteroides fragilis, Sutterella, Lachnospiraceae,
4-methyl-2-pentanone, 1-butanol, and 2-butanone might help to categorize patients at risk of
NAFLD/NASH. In NASH subjects, lower levels of Oscillospira were associated with higher levels of
Dorea and Ruminococcus. It was suggested that the interrelated enterotype-metabotype framework
might help to discover a specific signature of disease progression. Notably, the relevant amount
of species such as Lachnospiraceae, Ruminococcus, and Dorea found in pediatric patients with NASH
might indicate that some modifications of microbiota can constitute a significant risk factor for liver
disease progression.
5. Conclusions and Future Perspectives
The pathogenesis of NASH is complex since many events occur in parallel. IR, adipocyte
proliferation, and changes in the intestinal flora seem to have a relevant role. Adipokines such
as IL-6 and TNF-α produced by adipocytes can influence the hepatocyte fat content, favoring liver
tissue inflammation. Free fatty acids and free cholesterol induce endoplasmic reticulum stress and
oxidative stress resulting in hepatic inflammation and fibrogenesis [2]. This complexity at least partially
explains the lack of a consolidated therapeutic approach and the difficulties in diagnostic assessment.
Metabolomics might be one of the most stimulating ways to analyze the metabolic alterations
associated with NASH [9]. The quickly expanding research field of metabolomics involves the study
of the molecular species smaller than <1.5 kDa in any fluid, cell, or tissue [45–47].
The liver shows some peculiar patterns that make it the ideal context for metabolomic study.
In fact, no other organ or tissue processes such a plethora of lipids and water-soluble substances [11].
Many authors have proposed non-invasive markers of liver disease that might discriminate the
early stages of damage, thus helping clinicians in the diagnostic process [8]. Dong et al. [38] worked
in this direction with an interesting study. They developed a panel of urinary biomarkers that might
help to discriminate between NAFL and NASH. The comparison between NAFL and NASH showed
that the most relevant differences were about nucleic acids and amino acids that represent an adaptive
physiological response to liver stress. The level of cholinesterase was significantly lower in patients
with NASH in comparison with NAFL. Low cholinesterase levels can have a negative impact on the
synthesis and secretion of very low-density lipoprotein. Remarkably, it was also demonstrated that
indoleacetic acid was higher in patients with NASH in comparison with NAFL. Notably, the major
differences between NAFL and NASH concern energy impairment. Indeed, future research studies
might go in this direction. Unfortunately, many critical points can be registered. First of all, gender,
ethnicity, age, nutritional status, and presence of comorbidities might lead to significant differences
in the single molecule threshold of normality [48]. The identification of patients at risk for NASH
development and progression remains an unresolved challenge.
A greater understanding of the evolution of NAFLD/NASH should evaluate the role of lipid,
glucose, amino acids, and BAs metabolism. The study of biomarkers associated to the main metabolic
process involved in NASH pathogenesis might lead to the development of new therapeutic options.
In general, the most important issue for an effective prevention program depends on the early
detection, treatment, and monitoring of high-risk subjects. This aim can be reached through the
quantification of the disease-specific biomarkers summarized in this review.
In this complex context, a translational approach might be more effective. An important
translational study with animal models and humans was developed by parallel analyses among
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Gnmt-KO mice, NAFLD patients, and HC [35]. In NAFLD samples, the levels of organic acids, PC,
LPC, arachidonic acid, glutamic acid, Bas, and sphingomyelin lipids were significantly different in
comparison with HC. Many differences in antioxidative ether glycerophospholipids, sn-2 arachidonly
diacylglycerophosphocholine, and free arachidonic acid emerged between NAFL and NASH.
The possible application of the cited studies in clinical practice represents a main issue. Indeed,
the study by Zhou et al. [43] and the development of NASH ClinLipMet score is an important turning
point and should be a model for further studies.
Another main future perspective concerns the possible prevention of hepatocellular carcinoma
(HCC) onset. Although this is not the principal aim of the present review, we would like to cite the
study by Teilhet et al. [49]. They performed a comparative metabolomics study between patients with
NASH-related cirrhosis and non-cirrhotic NAFLD who underwent hepatectomy for HCC. The study
included 28 pairs of HCC samples versus Non-Tumoral Tissue (NTT). In HCC tissue, compared to
NTT, high levels of lactate and phosphocholine, and low glucose were detected. High levels of
β-hydroxybutyrate, tyrosine, phenylalanine, and histidine were revealed in patients with cirrhosis
compared to non-cirrhotic ones. On the contrary, major levels of glutamine/glutamate were described
in non-cirrhotic patients in comparison with the others.
The available studies showed that there are clear differences in the metabolomic patterns of
healthy subjects and patients with NAFLD. However, to differentiate patients with NAFL and those
with NASH remains a true challenge. Actually, only a few metabolites were significantly different
between NAFL and NASH. In the future, it would be necessary to develop large cohort studies with the
aim of evaluating the metabolomics and histological differences between NAFL and NASH in parallel.
In the future, biomarkers might become important in every-day clinical practice, especially for
the early diagnosis of high-risk patients. Moreover, the metabolomics approach could favor the
development of personalized behavioral, diet, and drug-based therapy.
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